French urological device company deletes Europe market listing:
This article was originally published in Clinica
Executive Summary
An ongoing and "significant" decline in the liquidity of the ADSs of EDAP TMS has prompted the French producer of minimally invasive urological devices to seek delisting from Nasdaq Europe. The move, decided on February 11 and requested by the Vaulx-en-Velin company on February 28, will take place on April. The US Nasdaq listing will not be affected. CEO Eric Simon said that continued trading on the European Nasdaq did not add sufficient value for EDAP or its shareholders.